Found: 15
Select item for more details and to access through your institution.
The Impact of Smoking on Relapse and Survival in Patients with Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia Treated with the Combination of Intensive Therapy with Tyrosine Kinase Inhibitor.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2019, v. 19, p. S180, doi. 10.1016/j.clml.2019.07.014
- By:
- Publication type:
- Article
The Early Achievement of Measurable Residual Disease Negativity in the Treatment of Adults with Philadelphia-Negative B-Cell Acute Lymphoblastic Leukemia is a Strong Predictor for Survival.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2019, v. 19, p. S193, doi. 10.1016/j.clml.2019.07.040
- By:
- Publication type:
- Article
Hyper-CVAD Plus Ofatumumab as Frontline Therapy for Adults with CD20 Positive Acute Lymphoblastic Leukemia.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2019, v. 19, p. S185, doi. 10.1016/j.clml.2019.07.023
- By:
- Publication type:
- Article
Inotuzumab Ozogamicin Combined with Low-Intensity, with or without Blinatumomab vs. Intensive Therapy for Older Patients with Newly Diagnosed Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia: A Propensity Score Analysis.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2019, v. 19, p. S181, doi. 10.1016/j.clml.2019.07.016
- By:
- Publication type:
- Article
Dynamic Prediction of Outcome with Longitudinal BCR-ABL1 Levels in Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2019, v. 19, p. S180, doi. 10.1016/j.clml.2019.07.015
- By:
- Publication type:
- Article
Frontline Ofatumumab with Hyper-CVAD in CD20+ Acute Lymphoblastic Leukemia (ALL): Updated Results of a Phase II Trial.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2017, v. 17, p. S256, doi. 10.1016/j.clml.2017.07.020
- By:
- Publication type:
- Article
Frontline Therapy with Combination of Hyper-CVAD with Ponatinib in Patients (Pts) with Philadelphia Chromosome-Positive (Ph+) ALL (ALL): A Phase II Study.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2016, v. 16, p. S10, doi. 10.1016/j.clml.2016.07.017
- By:
- Publication type:
- Article
Update Results of Frontline Therapy with Combination of Hyper-CMAD with Liposomal Vincristine (M) in Patients (Pts) with ALL (ALL).
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2016, v. 16, p. S11, doi. 10.1016/j.clml.2016.07.018
- By:
- Publication type:
- Article
Utility of Day 14 Bone Marrow Evaluation in Adults with Philadelphia Chromosome-Negative ALL: Relationship with Minimal Residual Disease Status.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2016, v. 16, p. S14, doi. 10.1016/j.clml.2016.07.021
- By:
- Publication type:
- Article
Updated Results from the Phase II Study of Hyper-CVAD in Combination with Ofatumumab as Frontline Therapy for Adults with CD20 Positive (CD20+) ALL.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2016, v. 16, p. S6, doi. 10.1016/j.clml.2016.07.010
- By:
- Publication type:
- Article
A phase II study of omacetaxine mepesuccinate for patients with higher‐risk myelodysplastic syndrome and chronic myelomonocytic leukemia after failure of hypomethylating agents.
- Published in:
- American Journal of Hematology, 2019, v. 94, n. 1, p. 74, doi. 10.1002/ajh.25318
- By:
- Publication type:
- Article
Outcomes of adults with relapsed or refractory Burkitt and high-grade B-cell leukemia/lymphoma.
- Published in:
- American Journal of Hematology, 2017, v. 92, n. 6, p. E114, doi. 10.1002/ajh.24720
- By:
- Publication type:
- Article
Poor outcomes associated with +der(22)t(9;22) and −9/9p in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia receiving chemotherapy plus a tyrosine kinase inhibitor.
- Published in:
- American Journal of Hematology, 2017, v. 92, n. 3, p. 238, doi. 10.1002/ajh.24625
- By:
- Publication type:
- Article
Chemoimmunotherapy with inotuzumab ozogamicin combined with mini-hyper-CVD, with or without blinatumomab, is highly effective in patients with Philadelphia chromosome-negative acute lymphoblastic leukemia in first salvage.
- Published in:
- 2018
- By:
- Publication type:
- journal article
Hyper-CVAD plus ofatumumab versus hyper-CVAD plus rituximab as frontline therapy in adults with Philadelphia chromosome-negative acute lymphoblastic leukemia: A propensity score analysis.
- Published in:
- 2021
- By:
- Publication type:
- journal article